Tags

Type your tag names separated by a space and hit enter

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
J Am Coll Cardiol. 2017 Sep 05; 70(10):1290-1301.JACC

Abstract

Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.

Authors+Show Affiliations

Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario, Canada.Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville, Maryland.Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago, Illinois.Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris, France.Department of Medicine, University of Vancouver, British Columbia, Canada.Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan, Italy.Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee.Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina.Department of Epidemiology, University of Alabama Birmingham, Birmingham, Alabama.Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.Department of Vascular Medicine, AMC, Amsterdam, the Netherlands.Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford, Connecticut.Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario, Canada.Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth, Western Australia.Division of Cardiology, Hartford Hospital, Hartford, Connecticut.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28859793

Citation

Rosenson, Robert S., et al. "Optimizing Cholesterol Treatment in Patients With Muscle Complaints." Journal of the American College of Cardiology, vol. 70, no. 10, 2017, pp. 1290-1301.
Rosenson RS, Baker S, Banach M, et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol. 2017;70(10):1290-1301.
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., Moriarty, P. M., Morris, P. B., Muntner, P., Ray, K. K., Stroes, E. S., Taylor, B. A., Taylor, V. H., Watts, G. F., & Thompson, P. D. (2017). Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology, 70(10), 1290-1301. https://doi.org/10.1016/j.jacc.2017.07.752
Rosenson RS, et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol. 2017 Sep 5;70(10):1290-1301. PubMed PMID: 28859793.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optimizing Cholesterol Treatment in Patients With Muscle Complaints. AU - Rosenson,Robert S, AU - Baker,Steven, AU - Banach,Maciej, AU - Borow,Kenneth M, AU - Braun,Lynne T, AU - Bruckert,Eric, AU - Brunham,Liam R, AU - Catapano,Alberico L, AU - Elam,Marshall B, AU - Mancini,G B John, AU - Moriarty,Patrick M, AU - Morris,Pamela B, AU - Muntner,Paul, AU - Ray,Kausik K, AU - Stroes,Erik S, AU - Taylor,Beth A, AU - Taylor,Valerie H, AU - Watts,Gerald F, AU - Thompson,Paul D, PY - 2017/05/21/received PY - 2017/07/20/revised PY - 2017/07/21/accepted PY - 2017/9/2/entrez PY - 2017/9/2/pubmed PY - 2017/9/14/medline KW - cardiovascular disease KW - low-density lipoprotein KW - myalgia KW - myopathy KW - statin intolerance SP - 1290 EP - 1301 JF - Journal of the American College of Cardiology JO - J. Am. Coll. Cardiol. VL - 70 IS - 10 N2 - Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms. SN - 1558-3597 UR - https://www.unboundmedicine.com/medline/citation/28859793/Optimizing_Cholesterol_Treatment_in_Patients_With_Muscle_Complaints_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(17)38966-0 DB - PRIME DP - Unbound Medicine ER -